Similarly, in cardiovascular diseases, targeting PCSK9 lowers cholesterol levels, while NLRP3 knockout reduces myocardial inflammation, improving atherosclerosis and decreasing cardiovascular event risk (Makhmudova et al., 2024). The gene discussed is NLRP3; the disease is cardiovascular disorder.